PLA General Hospital of Chengdu Military Region

Chengdu, China

PLA General Hospital of Chengdu Military Region

Chengdu, China
SEARCH FILTERS
Time filter
Source Type

Jian C.-X.,Chongqing Medical University | Liu X.-F.,General Hospital of Jinan Military Region of PLA | Hu J.,Chongqing Medical University | Li C.-J.,PLA General Hospital of Chengdu Military Region | And 4 more authors.
European Journal of Pharmacology | Year: 2013

20-Hydroxyecdysone, an ecdysteroid hormone, can induce osteogenic differentiation in mesenchymal stem cells. Periodontal ligament stem cells (PDLS cells) have mesenchymal-stem-cell-like qualities and are considered as one of the candidates of future clinical application in periodontitis treatment. However, there are no studies describing the effect of 20-Hydroxyecdysone on PDLS cells. In this paper, we report a detailed study on the effect of 20-Hydroxyecdysone on PDLS cell proliferation in vitro. PDLS cells were developed from human PDL cells and were treated with 20-Hydroxyecdysone to understand different aspects of its effects. 20-Hydroxyecdysone promoted PDLS cell proliferation; significantly increased the gene expression levels of runt-related transcription factor 2, alkaline phosphatase (ALP), type I collagen, and osteocalcin. Moreover, 20-Hydroxyecdysone enhanced bone formation by PDLS cells and significantly increased bone morphogenetic protein-2 (BMP-2) mRNA and protein expression. However, 20-Hydroxyecdysonemediated increase in ALP activity was blocked with a BMP-2-specific neutralizing antibody or with the antagonist noggin; and20-Hydroxyecdysone mediated induction of BMP-2 expression and increase of ALP activity were abolished by the extracellular regulated protein kinase (ERK) MAPK pathway inhibitor PD98059. 20-Hydroxyecdysone also increased the phosphorylation of ERK. These findings provide evidence to state that 20-Hydroxyecdysone stimulates cell proliferation and induces osteogenic differentiation through the induction of BMP-2 expression in PDLS cells. It also shows that the ERK pathway is involved in 20-Hydroxyecdysone induced BMP-2 expression and osteogenic differentiation. These results are suggesting its potential as a drug for periodontal regenerative therapy. © 2012 Elsevier B.V. All rights reserved.


Huang Z.-B.,Sichuan University | Yin G.-F.,Sichuan University | Liao X.-M.,Sichuan University | Gu J.-W.,PLA General Hospital of Chengdu Military Region
Frontiers of Materials Science | Year: 2014

Polypyrrole (PPy), the earliest prepared conducting polymer, has good biocompatibility, easy synthesis and flexibility in processing. Compared with metal and inorganic materials, doped PPy has better mechanical match with live tissue, resulting in its many applications in biomedical field. This mini-review presents some information on specific PPy properties for tissue engineering applications, including its synthesis, doping, bio-modification. Although some challenges and unanswered problems still remain, PPy as novel biomaterial has promoted the development tissue engineering for its clinical application in the future. © 2014 Higher Education Press and Springer-Verlag Berlin Heidelberg.


PubMed | b Chengdu Military Garrison Center for Disease Control and Prevention and PLA General Hospital of Chengdu Military Region
Type: Journal Article | Journal: Organogenesis | Year: 2016

Periodontal ligament stem cells (PDLSCs) are tissue-specific mesenchymal stem cells (MSCs), having an important role in regenerative therapy for teeth loss. Interleukin-7 (IL-7) is a key cytokine produced by stromal cells including MSCs, and exhibits specific roles for B and T cell development and osteoblasts differentiation of multiple myeloma. However, the effect of IL-7 on osteogenic differentiation of PDLSCs remains unclear. Therefore, in the present study we determined whether IL-7 affects the proliferation and osteogenic differentiation of PDLSCs in vitro and explored the associated signaling pathways for IL-7-mediated cell differentiation. The results demonstrated that the isolated human PDLSCs possessed MSCs features, highly expressing CD90, CD44, CD105, CD29 and CD73, and almost did not expressed CD34, CD45, CD11b, CD14 and CD117. IL-7 could not significantly affect the proliferation of PDLSCs, but it decreased their osteogenic differentiation and inhibited alkaline phosphatase (ALP) activity. The results of quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting exhibited that the expression levels of Runx-2, SP7 and osteocalcin (OCN) were significantly reduced by IL-7. Further studies indicated that IL-7 did not significantly change JNK, ERK1/2 and p38 protein production, but markedly suppressed their phosphorylation levels. These data suggest that IL-7 inhibits the osteogenic differentiation of PDLSCs probably via inactivation of mitogen-activated protein kinase (MAPK) signaling pathway.


PubMed | Mount Sinai School of Medicine and PLA General Hospital of Chengdu Military Region
Type: Journal Article | Journal: Translational lung cancer research | Year: 2015

Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer (NSCLC). In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs published between January 2011 and May 2012 into a pooled analysis which had been published in 2011. Outcomes analyzed were objective response rate (ORR), progression free survival (PFS), overall survival (OS) and adverse events. Twenty trials including 9,005 patients were identified, and six of them were recently published. As first-line therapy compared to placebo or chemotherapy, there was a similar ORR (P=0.29 and 0.42), PFS (P=0.09 and 0.25) and OS (P=0.73 and 0.49). However, for the patients with EGFR mutations, erlotinib based regimens could significantly improve ORR (P<0.01), prolong PFS (P<0.0), but did not prolong OS (P=0.22). As maintenance therapy compared with placebo, erlotinib based regimens significantly increased ORR (P<0.01), prolonged PFS (P<0.01), but did not improve OS (P=0.22). As second/third-line therapy comparing with placebo, erlotinib based regimens also significantly increased ORR (P<0.01), prolonged PFS (P<0.01), and improved OS (P<0.01). As second/third-line therapy compared with chemotherapy, gefitinib, or vandetanib, the outcomes were similar between two arms. However, compared with PF299804, there was a decreased ORR (P=0.02), and shorten PFS (P=0.02). Meanwhile, The patients treated with erlotinib based regimens suffered from more diarrhea, rash, and less fatigue, neutropenia, and thrombocytopenia than other agent based regimens. Our meta analysis showed that erlotinib based regimens could significantly increase ORR, improve PFS as first-line maintenance therapy or second/third-line therapy comparing with placebo or PF299804.


Liu X.-C.,Chinese People's Liberation Army | Liu X.-F.,General Hospital of Jinan Military Region of PLA | Jian C.-X.,PLA General Hospital of Chengdu Military Region | Li C.-J.,PLA General Hospital of Chengdu Military Region | He S.-Z.,Chinese People's Liberation Army
Inflammation | Year: 2012

Age-related macular degeneration (AMD) is the predominant cause of irreversible blindness in the elderly population. Despite intensive basic and clinical research, its pathogenesis remains unclear. However, evidence suggests that immunological and inflammatory factors contribute to the pathogenesis of AMD. A newly identified cytokine, IL-33, appears to be an important pro-inflammatory cytokine promoting tissue inflammation. In this study, IL-33 was increased through amyloid-beta 1-40 (Aβ 1-40) stimulation and regulated inflammatory cytokines including IL-6, IL-8, IL-1β, and TNF-α secretion using different signaling pathways in retinal pigment epithelium (RPE) cells. Furthermore, ST2L, the important component of the IL-33 receptor, was significantly increased following recombinant human IL-33 stimulation in RPE cells. These findings suggest that IL-33-mediated inflammatory responses in RPE cells are involved in the pathogenesis of AMD. Greater understanding of the inflammatory effect of IL-33 and its role in RPE cells should aid the development of future clinical therapeutics and enable novel pharmacological approaches towards the prevention of AMD. © 2011 Springer Science+Business Media, LLC.


Jian C.,Chongqing Medical University | Jian C.,PLA General Hospital of Chengdu Military Region | Li C.,PLA General Hospital of Chengdu Military Region | Ren Y.,PLA General Hospital of Chengdu Military Region | And 5 more authors.
Inflammation | Year: 2014

Periodontitis is a chronic inflammatory disease characterized by the destruction of tooth supporting tissues. Hypoxia, the mainly changes of the plateau environment, can induce severe periodontitis by animal experiments. There is, however, very little information on hypoxia and lipopolysaccharide (LPS) induced cytokine expression in periodontal ligament (PDL) cells. In this article, we characterized hypoxia or P. gingivalis lipopolysaccharide (Pg LPS) induced tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, and IL-6 expression by human periodontal ligament (hPDL) cells. We found that hypoxia augmented Pg LPS induced TNF-α, IL-1β, and IL-6 expression in hPDL cells. We also demonstrated that nuclear factor kappa B pathway was involved in hypoxia augmenting Pg LPS induced cytokine expression in hPDL cells. Thus, our results suggest that the hypoxic environment may enhance the immune function of hPDL cells that is induced by Pg LPS. © 2014, Springer Science+Business Media New York.


PubMed | Chongqing Medical University and PLA General Hospital of Chengdu Military Region
Type: Journal Article | Journal: Genetics and molecular research : GMR | Year: 2016

There is high incidence of periodontal disease in high-altitude environments; hypoxia may influence the proliferation and clone-forming ability of periodontal ligament stem cells (PDLSCs). The MAPK signaling pathway is closely correlated with cell proliferation, differentiation, and apoptosis. Thus, we isolated and cultured PDLSCs under hypoxic conditions to clarify the impact of hypoxia on PDLSC proliferation and the underlying mechanism. PDLSCs were separated and purified by the limiting dilution method and identified by flow cytometry. PDLSCs were cultured under hypoxic or normoxic conditions to observe their cloning efficiency. PDLSC proliferation at different oxygen concentrations was evaluated by MTT assay. Expression of p38/MAPK and MAPK/ERK signaling pathway members was detected by western blotting. Inhibitors for p38/MAPK or ERK were applied to PDLSCs to observe their impacts on clone formation and proliferation. Isolated PDLSCs exhibited typical stem cell morphological characteristics, strong abilities of globular clone formation and proliferation, and upregulated expression of mesenchymal stem cell markers. Stem cell marker expression was not statistically different between PDLSCs cultured under hypoxia and normoxia (P > 0.05). The clone number in the hypoxia group was significantly higher than that in the control (P < 0.05). PDLSC proliferation under hypoxia was higher than that of the control (P < 0.001). p38 and ERK1/2 phosphorylation in hypoxic PDLSCs was markedly enhanced compared to that in the control (P < 0.05). Either P38/MAPK inhibitor or ERK inhibitor treatment reduced clone formation and proliferation. Therefore, hypoxia enhanced PDLSC clone formation and proliferation by activating the p38/MAPK and ERK/MAPK signaling pathways.


Cheng P.,PLA General Hospital of Chengdu Military Region | Su X.,PLA General Hospital of Chengdu Military Region | Gao H.,PLA General Hospital of Chengdu Military Region | Zhang T.,PLA General Hospital of Chengdu Military Region
European Journal of Gynaecological Oncology | Year: 2013

Objective: Investigating the clinical and imaging features of bone metastasis in breast cancer, in order to raise early diagnosis level and to avoid misdiagnosis. Materials and Methods: An analysis of imaging of breast cancer bone metastasis by consulting relevant literatures. The authors also performed bone biopsy in the patient presented. Results: Biopsy results show that ductal carcinoma can be seen in bone marrow and in immune markers CK (+) and CD68 (-). Conclusion: Multiple systemic metastases are common for breast cancer, but it is rare that one patient has metastasis in all vertebrae. The positive rate of ordinary X-ray is lower than magnetic resonance imaging (MRI) or positron emission tomography/computed tomography (PET/CT) for detecting bone metastasis, but if an accurate diagnosis is to be made, all the imaging and clinical data should be combined.


Du M.,PLA General Hospital of Chengdu Military Region | Su X.-M.,PLA General Hospital of Chengdu Military Region | Zhang T.,PLA General Hospital of Chengdu Military Region | Xing Y.-J.,Affiliated Stomatological Hospital
Molecular Medicine Reports | Year: 2014

Bone morphogenetic protein 2 (BMP2) is a growth factor that is involved in the development and progression of various types of cancer. However, the epigenetic regulation of the expression of BMP2 and the association between BMP2 expression and drug resistance in breast cancer remains to be elucidated. The present study reported that the expression of BMP2 was significantly decreased in primary breast cancer samples and the MCF-7/ADR breast cancer mulitdrug resistance cell line, which was closely associated with its promoter DNA methylation status. The expression of BMP2 in MCF-7/ADR cells markedly increased when treated with 5-Aza-2′-deoxycytidine. Knockdown of BMP2 by specific small interfering RNA enhanced the chemoresistance of the MCF-7 breast cancer cell line. These findings indicated that epigenetic silencing of BMP2 in breast cancer may be involved in breast cancer progression and drug resistance, and provided a novel prognostic marker and therapeutic strategy for breast cancer.


Zhang T.,PLA General Hospital of Chengdu Military Region | Ding X.,PLA General Hospital of Chengdu Military Region | Wei D.,PLA General Hospital of Chengdu Military Region | Cheng P.,PLA General Hospital of Chengdu Military Region | And 4 more authors.
Anti-Cancer Drugs | Year: 2010

There is no effective systemic therapy for patients with advanced hepatocellular carcinoma (HCC) except liver transplantation. Sorafenib, a multikinase inhibitor, has been shown to significantly increase overall survival (OS) in a randomized, placebo-controlled, phase III trial of patients with HCC (SHARP). The aim of this study was to evaluate the effectiveness of sorafenib for advanced HCC by carrying out a meta-analysis of randomized controlled trials that compared sorafenib-based therapy with other agent-based therapy. Randomized controlled trials comparing sorafenib or combined chemotherapy with placebo or combined chemotherapy in advanced HCC between 2000 and 2008 were identified and the data were extracted from reports. Outcomes analyzed were objective response rate, time to progression (TTP), OS, and toxicity. The summary hazard ratios (HRs), odds ratios, and their 95% confidence intervals (CIs) for mortality, objective response rate, and toxicity were estimated. All statistical tests were two-sided. Three trials including 924 patients were identified. Sorafenib-based chemotherapy was also associated with a 79% prolongation of TPP (HR=0.58, 95% CI=0.49-0.69, P<0.001), and a 37.3% increase in OS (HR=0.66, 95% CI=0.55-0.78, P<0.001). Despite significant increases in the frequencies of hand-foot syndrome and diarrhea in patients receiving sorafenib-containing chemotherapy, no significant difference in other toxic events was observed. This meta-analysis suggests that sorafenib-based chemotherapy is superior to placebo-based chemotherapy in terms of TPP and OS without increase in severe toxic effects. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Loading PLA General Hospital of Chengdu Military Region collaborators
Loading PLA General Hospital of Chengdu Military Region collaborators